10-Q 1 amwl-20230930.htm 10-Q 10-Q
0001393584Q3false--12-310.010.0110001393584us-gaap:FairValueMeasurementsRecurringMember2022-12-310001393584us-gaap:PendingLitigationMember2023-09-300001393584amwl:CcawJvLlcMember2020-01-012020-12-310001393584us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001393584us-gaap:NoncontrollingInterestMember2022-03-310001393584us-gaap:CostOfSalesMember2022-07-012022-09-300001393584us-gaap:CommonStockMember2022-01-012022-03-310001393584us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001393584us-gaap:CommonClassBMember2023-07-012023-09-300001393584us-gaap:CommonStockMember2022-09-300001393584us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001393584us-gaap:AccountsReceivableMember2023-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-07-012023-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-12-310001393584us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001393584us-gaap:PerformanceSharesMember2022-09-300001393584us-gaap:NoncontrollingInterestMember2021-12-310001393584amwl:CcawJvLlcMember2022-12-3100013935842023-07-012023-09-300001393584amwl:CcawJvLlcMember2022-07-012022-09-300001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2023-09-300001393584us-gaap:CommonStockMember2022-04-012022-06-300001393584us-gaap:CommonStockMemberamwl:SilverCloudHealthHoldingsIncMember2022-04-012022-06-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-12-310001393584us-gaap:ContractBasedIntangibleAssetsMember2023-09-3000013935842023-03-310001393584us-gaap:RelatedPartyMemberamwl:CcawJvLlcMember2023-09-300001393584us-gaap:ParentMember2023-03-310001393584us-gaap:TechnologyBasedIntangibleAssetsMember2023-09-300001393584us-gaap:CommonStockMember2022-07-012022-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-01-012020-12-310001393584us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100013935842022-03-310001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-07-012023-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2023-07-012023-09-300001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2023-07-012023-09-300001393584us-gaap:RestrictedStockMember2022-01-012022-09-300001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-07-012022-09-300001393584amwl:PlatformSubscriptionMember2023-01-012023-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-06-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001393584us-gaap:CommonStockMember2023-01-012023-03-310001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001393584amwl:ClevelandClinicMember2022-01-012022-09-300001393584us-gaap:PerformanceSharesMember2022-12-310001393584us-gaap:NoncontrollingInterestMember2022-12-310001393584us-gaap:RestrictedStockMember2023-01-012023-09-3000013935842022-12-310001393584us-gaap:DevelopedTechnologyRightsMember2022-12-310001393584us-gaap:SellingAndMarketingExpenseMember2022-01-012022-09-300001393584us-gaap:ParentMember2021-12-310001393584us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001393584us-gaap:CommonClassCMember2022-12-310001393584us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001393584us-gaap:TradeNamesMember2022-12-310001393584us-gaap:CommonStockMember2023-09-300001393584us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001393584us-gaap:CommonStockMember2022-03-310001393584us-gaap:CommonStockMemberamwl:EquityAwardPlanMember2023-09-300001393584us-gaap:CommonClassAMember2023-09-300001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2023-01-012023-09-300001393584us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001393584amwl:KurtKnightMember2023-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001393584us-gaap:PerformanceSharesMember2023-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2021-12-3100013935842022-01-012022-09-300001393584us-gaap:AdditionalPaidInCapitalMember2022-03-310001393584us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberamwl:RelatedPartyClientOneMember2022-01-012022-09-300001393584us-gaap:SellingAndMarketingExpenseMember2022-07-012022-09-300001393584us-gaap:NoncontrollingInterestMemberamwl:NtnMemberMember2023-09-300001393584amwl:UnvestedRestrictedStockMember2023-07-012023-09-300001393584amwl:OthersMember2023-07-012023-09-300001393584amwl:ConversaHealthIncMember2022-01-012022-03-310001393584us-gaap:RetainedEarningsAppropriatedMember2023-01-012023-03-310001393584amwl:CcawJvLlcMember2023-07-012023-09-300001393584us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001393584us-gaap:IndemnificationGuaranteeMember2022-01-012022-12-3100013935842022-04-012022-06-300001393584us-gaap:AdditionalPaidInCapitalMember2022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2023-06-300001393584us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001393584us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-3000013935842023-01-012023-09-300001393584us-gaap:ParentMember2022-07-012022-09-300001393584us-gaap:CustomerRelationshipsMember2022-12-310001393584us-gaap:RetainedEarningsAppropriatedMember2022-04-012022-06-300001393584us-gaap:CommonStockMember2023-04-012023-06-300001393584us-gaap:CommonClassBMember2023-10-270001393584amwl:CcawJvLlcMemberus-gaap:RelatedPartyMember2022-12-310001393584amwl:OthersMember2022-07-012022-09-300001393584us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001393584us-gaap:RestrictedStockMembersrt:MaximumMember2023-01-012023-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-04-132022-04-1300013935842023-06-300001393584amwl:ClevelandClinicMemberus-gaap:RelatedPartyMember2023-09-300001393584us-gaap:CommonStockMemberamwl:EquityAwardPlanMember2023-01-012023-09-300001393584amwl:ClientOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001393584us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001393584amwl:VisitsMember2022-07-012022-09-300001393584us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001393584us-gaap:ParentMember2022-12-310001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2022-07-012022-09-300001393584us-gaap:CommonClassAMember2022-12-310001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-310001393584amwl:OthersMember2022-01-012022-09-300001393584us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-3000013935842022-07-012022-09-3000013935842022-09-300001393584us-gaap:ParentMemberamwl:SilverCloudHealthHoldingsIncMember2022-04-012022-06-300001393584us-gaap:AdditionalPaidInCapitalMember2022-06-300001393584us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001393584us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-07-012022-09-300001393584us-gaap:AdditionalPaidInCapitalMember2023-03-310001393584amwl:VisitsMember2023-01-012023-09-300001393584us-gaap:CustomerConcentrationRiskMemberamwl:ClientOneMemberus-gaap:AccountsReceivableMember2023-01-012023-09-300001393584us-gaap:RestrictedStockUnitsRSUMember2023-09-300001393584us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310001393584amwl:NtnMemberMember2023-01-012023-09-300001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-09-300001393584amwl:CcawJvLlcMember2020-12-310001393584us-gaap:ParentMember2023-01-012023-03-310001393584us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001393584srt:MaximumMemberamwl:NtnMemberMember2016-01-010001393584us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001393584amwl:ClevelandClinicMember2022-07-012022-09-300001393584us-gaap:ParentMember2022-09-300001393584us-gaap:RestrictedStockUnitsRSUMember2022-12-310001393584us-gaap:CommonStockMember2021-12-310001393584us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001393584amwl:ConversaHealthIncMemberus-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001393584amwl:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2023-01-012023-09-300001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001393584us-gaap:RetainedEarningsAppropriatedMember2022-01-012022-03-3100013935842023-10-012023-09-300001393584us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001393584us-gaap:CustomerRelationshipsMember2023-09-300001393584amwl:PlatformSubscriptionMember2022-01-012022-09-300001393584us-gaap:AccountsReceivableMember2022-12-310001393584us-gaap:PerformanceSharesMember2023-01-012023-09-300001393584us-gaap:RestrictedStockMembersrt:MinimumMember2023-01-012023-09-300001393584us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001393584us-gaap:RelatedPartyMember2022-12-310001393584us-gaap:AdditionalPaidInCapitalMember2021-12-310001393584us-gaap:PerformanceSharesMember2022-01-012022-09-300001393584us-gaap:CommonClassBMember2023-01-012023-09-300001393584us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001393584amwl:ClevelandClinicMemberus-gaap:RelatedPartyMember2022-12-3100013935842022-06-300001393584us-gaap:PerformanceSharesMember2023-07-012023-09-300001393584us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001393584srt:ManagementMembersrt:MaximumMemberus-gaap:PerformanceSharesMember2023-09-300001393584amwl:SilverCloudHealthHoldingsIncMember2022-04-012022-06-300001393584us-gaap:CommonClassCMember2023-10-270001393584us-gaap:RetainedEarningsAppropriatedMember2022-03-3100013935842021-12-310001393584amwl:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2022-01-012022-09-300001393584us-gaap:NoncontrollingInterestMemberamwl:NtnMemberMember2022-12-310001393584us-gaap:CommonStockMember2023-07-012023-09-300001393584us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberamwl:RelatedPartyClientOneMember2023-07-012023-09-300001393584amwl:UnvestedRestrictedStockMember2022-07-012022-09-300001393584us-gaap:IndemnificationGuaranteeMember2023-01-012023-09-300001393584amwl:OthersMember2023-01-012023-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001393584amwl:CcawJvLlcMember2023-09-300001393584srt:MinimumMemberamwl:NtnMemberMember2016-01-010001393584amwl:PlatformSubscriptionMember2022-07-012022-09-300001393584us-gaap:NoncontrollingInterestMember2023-06-300001393584us-gaap:ParentMember2023-09-300001393584us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001393584amwl:ClevelandClinicMember2023-07-012023-09-300001393584us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001393584us-gaap:CommonStockMember2022-06-300001393584amwl:CcawJvLlcMember2022-01-012022-09-300001393584us-gaap:CommonStockMember2022-12-310001393584amwl:VisitsMember2023-07-012023-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001393584us-gaap:CommonStockMember2023-06-300001393584us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberamwl:RelatedPartyClientOneMember2022-07-012022-09-300001393584us-gaap:ParentMember2022-06-300001393584us-gaap:CostOfSalesMember2023-01-012023-09-300001393584us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001393584us-gaap:CommonStockMember2023-03-310001393584srt:MaximumMember2023-01-012023-09-300001393584us-gaap:ParentMember2022-01-012022-03-310001393584us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberamwl:RelatedPartyClientOneMember2023-01-012023-09-300001393584amwl:NtnMemberMember2022-07-012022-09-300001393584us-gaap:RelatedPartyMember2022-01-012022-09-300001393584amwl:KurtKnightMember2023-01-012023-09-300001393584us-gaap:RelatedPartyMember2022-07-012022-09-3000013935842023-09-300001393584us-gaap:AdditionalPaidInCapitalMember2022-12-310001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001393584amwl:NtnMemberMember2022-01-012022-09-300001393584us-gaap:DevelopedTechnologyRightsMember2023-09-300001393584amwl:UnvestedRestrictedStockMember2023-01-012023-09-300001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2022-01-012022-12-3100013935842023-01-012023-03-310001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-310001393584us-gaap:NoncontrollingInterestMember2022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-09-300001393584us-gaap:AdditionalPaidInCapitalMember2023-06-300001393584us-gaap:CommonClassAMember2023-10-270001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2023-01-012023-09-300001393584us-gaap:RelatedPartyMember2023-01-012023-09-300001393584us-gaap:AdditionalPaidInCapitalMemberamwl:SilverCloudHealthHoldingsIncMember2022-04-012022-06-300001393584us-gaap:CostOfSalesMember2022-01-012022-09-300001393584us-gaap:CostOfSalesMember2023-07-012023-09-300001393584us-gaap:AdditionalPaidInCapitalMember2023-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2023-04-012023-06-300001393584us-gaap:NoncontrollingInterestMember2022-06-300001393584us-gaap:ParentMember2023-07-012023-09-300001393584amwl:UnvestedRestrictedStockMember2022-01-012022-09-300001393584amwl:ClevelandClinicMember2023-09-300001393584us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-3000013935842023-04-012023-06-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001393584srt:ManagementMemberus-gaap:PerformanceSharesMember2023-01-012023-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-09-300001393584us-gaap:ContractBasedIntangibleAssetsMember2022-12-310001393584us-gaap:RetainedEarningsAppropriatedMember2023-03-310001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-09-300001393584us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001393584us-gaap:CommonClassBMember2023-09-300001393584us-gaap:NoncontrollingInterestMember2023-09-300001393584amwl:NtnMemberMember2023-07-012023-09-300001393584us-gaap:TradeNamesMember2023-09-300001393584us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001393584us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-09-300001393584us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001393584us-gaap:FairValueMeasurementsRecurringMember2023-09-300001393584amwl:ConversaHealthIncMemberus-gaap:ParentMember2022-01-012022-03-310001393584amwl:ClevelandClinicMember2023-01-012023-09-300001393584amwl:ClevelandClinicMember2022-12-310001393584us-gaap:RelatedPartyMember2023-09-300001393584us-gaap:ParentMember2023-04-012023-06-300001393584us-gaap:CustomerConcentrationRiskMemberamwl:ClientTwoMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001393584us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001393584amwl:PlatformSubscriptionMember2023-07-012023-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2023-09-300001393584us-gaap:NoncontrollingInterestMember2023-03-310001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000013935842022-01-012022-12-310001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2022-01-012022-09-3000013935842022-01-012022-03-310001393584us-gaap:CommonClassBMember2022-12-310001393584us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001393584amwl:VisitsMember2022-01-012022-09-300001393584us-gaap:RelatedPartyMember2023-07-012023-09-300001393584us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001393584us-gaap:RetainedEarningsAppropriatedMember2022-07-012022-09-300001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-09-300001393584us-gaap:ParentMember2023-06-300001393584us-gaap:ParentMember2022-04-012022-06-300001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2022-01-012022-09-300001393584amwl:ConversaHealthIncMemberus-gaap:CommonStockMember2022-01-012022-03-310001393584us-gaap:ParentMember2022-03-310001393584us-gaap:CustomerConcentrationRiskMemberamwl:ClientTwoMemberus-gaap:AccountsReceivableMember2023-01-012023-09-300001393584amwl:CcawJvLlcMember2023-01-012023-09-300001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2022-12-310001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001393584us-gaap:PendingLitigationMember2022-12-310001393584us-gaap:CommonClassCMember2023-09-300001393584us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000013935842023-01-012022-12-31amwl:Segmentxbrli:purexbrli:sharesamwl:Trancheiso4217:USDxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

Commission File Number: 001-39515

 

American Well Corporation

(Exact name of registrant as specified in its charter)

 

 

Delaware

20-5009396

(State of incorporation)

(I.R.S. Employer
Identification Number)

 

75 State Street, 26th Floor

Boston, MA 02109

(Address of registrant’s principal executive offices)

(617) 204-3500

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Class A common stock,
par value of $0.01 per share

 

AMWL

 

The New York Stock Exchange

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

Accelerated filer

 

Non-accelerated filer

 

Smaller reporting company

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

 

As of October 27, 2023, the number of shares of the registrant’s Class A common stock outstanding was 254,623,284, the number of shares of the registrant’s Class B common stock outstanding was 27,390,397 and the number of shares of the registrant’s Class C common stock outstanding was 5,555,555.

 

 

 


 

American Well Corporation

QUARTERLY REPORT ON FORM 10-Q

For the period ended September 30, 2023

TABLE OF CONTENTS

 

Page

PART I

Financial Information

3

Item 1.

Financial Statements

3

 

Condensed Consolidated Balance Sheet as of September 30, 2023 (unaudited) and December 31, 2022

3

 

Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2023 and 2022

4

 

Condensed Consolidated Statement of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2023 and 2022

5

 

Condensed Consolidated Statement of Cash Flows (unaudited) for the nine months ended September 30, 2023 and 2022

7

Notes to the Unaudited Condensed Consolidated Financial Statements

8

Item 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

34

PART II

Other Information

35

Item 1.

Legal Proceedings

35

Item 1A.

Risk Factors

35

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

35

Item 3.

Defaults Upon Senior Securities

35

Item 4.

Mine Safety Disclosures

35

Item 5.

Other Information

36

Item 6.

Exhibits

36

 

 

 

 


 

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)

 

 

September 30, 2023

 

 

December 31, 2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

319,373

 

 

$

538,546

 

Investments

 

 

98,717

 

 

 

 

Accounts receivable ($91 and $2,597, from related parties and net of
   allowances of $
1,944 and $1,884, respectively)

 

 

46,713

 

 

 

58,372

 

Inventories

 

 

7,832

 

 

 

8,737

 

Deferred contract acquisition costs

 

 

1,929

 

 

 

1,394

 

Prepaid expenses and other current assets

 

 

14,275

 

 

 

19,567

 

Total current assets

 

 

488,839

 

 

 

626,616

 

Restricted cash

 

 

795

 

 

 

795

 

Property and equipment, net

 

 

576

 

 

 

1,012

 

Goodwill

 

 

 

 

 

435,279

 

Intangible assets, net

 

 

125,889

 

 

 

134,980

 

Operating lease right-of-use asset

 

 

11,247

 

 

 

13,509

 

Deferred contract acquisition costs, net of current portion

 

 

3,598

 

 

 

3,394

 

Other assets

 

 

2,164

 

 

 

1,972

 

Investment in minority owned joint venture (Note 2)

 

 

1,893

 

 

 

 

Total assets

 

$

635,001

 

 

$

1,217,557

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

4,823

 

 

$

7,236

 

Accrued expenses and other current liabilities

 

 

37,378

 

 

 

54,258

 

Operating lease liability, current

 

 

3,402

 

 

 

3,057

 

Deferred revenue ($154 and $1,665 from related parties, respectively)

 

 

53,076

 

 

 

49,505

 

Total current liabilities

 

 

98,679

 

 

 

114,056

 

Other long-term liabilities

 

 

1,586

 

 

 

1,574

 

Operating lease liability, net of current portion

 

 

9,086

 

 

 

11,787

 

Deferred revenue, net of current portion ($0 and $10 from related
   parties, respectively)

 

 

5,954

 

 

 

6,289

 

Total liabilities

 

 

115,305

 

 

 

133,706

 

Commitments and contingencies (Note 10)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares
   issued or outstanding as of September 30, 2023 and as of December 31, 2022

 

 

 

 

 

 

Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 254,038,177 and
   
244,193,727 shares issued and outstanding, respectively; 100,000,000 Class B shares authorized,
   
27,390,397 shares issued and outstanding; 200,000,000 Class C shares authorized 5,555,555 issued
   and outstanding as of September 30, 2023 and as of December 31, 2022

 

 

2,864

 

 

 

2,766

 

Additional paid-in capital

 

 

2,222,152

 

 

 

2,160,108

 

Accumulated other comprehensive income

 

 

(13,552

)

 

 

(16,969

)

Accumulated deficit

 

 

(1,709,191

)

 

 

(1,082,028

)

Total American Well Corporation stockholders’ equity

 

 

502,273

 

 

 

1,063,877

 

Non-controlling interest

 

 

17,423

 

 

 

19,974

 

Total stockholders’ equity

 

 

519,696

 

 

 

1,083,851

 

Total liabilities and stockholders’ equity

 

$

635,001

 

 

$

1,217,557

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


 

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

($1,044, $729, $3,015 and $3,106 from related parties, respectively)

 

$

61,922

 

 

$

69,209

 

 

$

188,370

 

 

$

197,957

 

Costs and operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Costs of revenue, excluding depreciation and amortization of intangible assets

 

 

40,457

 

 

 

41,507

 

 

 

117,453

 

 

 

114,769

 

Research and development

 

 

27,715

 

 

 

36,254

 

 

 

79,480

 

 

 

110,802

 

Sales and marketing

 

 

20,379

 

 

 

18,493

 

 

 

64,659

 

 

 

58,368

 

General and administrative

 

 

29,571

 

 

 

37,682

 

 

 

102,260

 

 

 

105,309

 

Depreciation and amortization expense

 

 

8,266

 

 

 

6,397

 

 

 

23,227

 

 

 

19,719

 

Goodwill Impairment

 

 

78,894

 

 

 

 

 

 

436,479

 

 

 

 

Total costs and operating expenses

 

 

205,282

 

 

 

140,333

 

 

 

823,558

 

 

 

408,967

 

Loss from operations

 

 

(143,360

)

 

 

(71,124

)

 

 

(635,188

)

 

 

(211,010

)

Interest income and other income (expense), net

 

 

7,978

 

 

 

1,237

 

 

 

11,250

 

 

 

2,109

 

Loss before expense from income taxes and loss from
   equity method investment

 

 

(135,382

)

 

 

(69,887

)

 

 

(623,938

)

 

 

(208,901

)

Expense from income taxes

 

 

(1,122

)

 

 

(95

)

 

 

(3,313

)

 

 

(224

)

Loss from equity method investment

 

 

(600

)

 

 

(593

)

 

 

(1,877

)

 

 

(1,355

)

Net loss

 

 

(137,104

)

 

 

(70,575

)

 

 

(629,128

)

 

 

(210,480

)

Net loss attributable to non-controlling interest

 

 

(690

)

 

 

(491

)

 

 

(2,551

)

 

 

(1,214

)

Net loss attributable to American Well Corporation

 

$

(136,414

)

 

$

(70,084

)

 

$

(626,577

)

 

$

(209,266

)

Net loss per share attributable to common stockholders,
   basic and diluted

 

$

(0.48

)

 

$

(0.25

)

 

$

(2.21

)

 

$

(0.77

)

Weighted-average common shares outstanding, basic and diluted

 

 

285,900,811

 

 

 

277,389,730

 

 

 

282,982,875

 

 

 

272,846,985

 

Net loss

 

$

(137,104

)

 

$

(70,575

)

 

$

(629,128

)

 

$

(210,480

)

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale investments

 

 

(3,190

)

 

 

1,002

 

 

 

3,062

 

 

 

(360

)

Foreign currency translation

 

 

(1,493

)

 

 

(11,213

)

 

 

355

 

 

 

(24,343

)

Comprehensive loss

 

 

(141,787

)

 

 

(80,786

)

 

 

(625,711

)

 

 

(235,183

)

Less: Comprehensive loss attributable to
   non-controlling interest

 

 

(690

)

 

 

(491

)

 

 

(2,551

)

 

 

(1,214

)

Comprehensive loss attributable to American Well Corporation

 

$

(141,097

)

 

$

(80,295

)

 

$

(623,160

)

 

$

(233,969

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


 

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(unaudited)

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

American Well
Corporation
Stockholders’

 

 

Noncontrolling

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

 

Interest

 

 

Equity

 

Balances as of January 1, 2023

 

 

277,139,679

 

 

$

2,766

 

 

$

2,160,108

 

 

$

(16,969

)

 

$

(1,082,028

)

 

$

1,063,877

 

 

$

19,974

 

 

$

1,083,851

 

Exercise of common stock options

 

 

128,572

 

 

 

1

 

 

 

288

 

 

 

 

 

 

 

 

 

289

 

 

 

 

 

 

289

 

Vesting of restricted stock units, including units with a market condition

 

 

2,927,471

 

 

 

29

 

 

 

(29

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares repurchased and retired

 

 

(316

)

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

(1

)

 

 

 

 

 

(1

)

Issuance of stock under employee stock purchase plan

 

 

513,339

 

 

 

5

 

 

 

1,263

 

 

 

 

 

 

 

 

 

1,268

 

 

 

 

 

 

1,268

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

20,997

 

 

 

 

 

 

 

 

 

20,997

 

 

 

 

 

 

20,997

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

2,062

 

 

 

 

 

 

2,062

 

 

 

 

 

 

2,062

 

Unrealized gains on available-for-
   sale securities, net of tax

 

 

 

 

 

 

 

 

 

 

 

4,319

 

 

 

 

 

 

4,319

 

 

 

 

 

 

4,319

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(397,688

)

 

 

(397,688

)

 

 

(821

)

 

 

(398,509

)

Balances as of March 31, 2023

 

 

280,708,745

 

 

 

2,801

 

 

 

2,182,627

 

 

 

(10,588

)

 

 

(1,479,717

)

 

 

695,123

 

 

 

19,153

 

 

 

714,276

 

Exercise of common stock options

 

 

158,027

 

 

 

2

 

 

 

278

 

 

 

 

 

 

 

 

 

280

 

 

 

 

 

 

280

 

Vesting of restricted stock units, including units with a market condition

 

 

3,420,846

 

 

 

34

 

 

 

(34

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares repurchased and retired

 

 

(264,671

)

 

 

(3

)

 

 

3

 

 

 

 

 

 

(585

)

 

 

(585

)

 

 

 

 

 

(585

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

21,513

 

 

 

 

 

 

 

 

 

21,513

 

 

 

 

 

 

21,513

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

(214

)

 

 

 

 

 

(214

)

 

 

 

 

 

(214

)

Unrealized gains on available-for-
   sale securities, net of tax

 

 

 

 

 

 

 

 

 

 

 

1,933

 

 

 

 

 

 

1,933

 

 

 

 

 

 

1,933

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(92,475

)

 

 

(92,475

)

 

 

(1,040

)

 

 

(93,515

)

Balances as of June 30, 2023

 

 

284,022,947

 

 

 

2,834

 

 

 

2,204,387

 

 

 

(8,869

)

 

 

(1,572,777

)

 

 

625,575

 

 

 

18,113

 

 

 

643,688

 

Exercise of common stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of restricted stock units

 

 

2,250,209

 

 

 

23

 

 

 

(23

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of stock under employee stock purchase plan

 

 

710,973

 

 

 

7

 

 

 

889

 

 

 

 

 

 

 

 

 

896

 

 

 

 

 

 

896

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

16,899

 

 

 

 

 

 

 

 

 

16,899

 

 

 

 

 

 

16,899

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

(1,493

)

 

 

 

 

 

(1,493

)

 

 

 

 

 

(1,493

)

Unrealized losses on available-for-
   sale securities, net of tax

 

 

 

 

 

 

 

 

 

 

 

(3,190

)

 

 

 

 

 

(3,190

)

 

 

 

 

 

(3,190

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(136,414

)

 

 

(136,414

)

 

 

(690

)

 

 

(137,104

)

Balances as of September 30, 2023

 

 

286,984,129

 

 

$

2,864

 

 

$

2,222,152

 

 

$

(13,552

)

 

$

(1,709,191

)

 

$

502,273

 

 

$

17,423

 

 

$

519,696

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(unaudited)

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

American
Well
Corporation
Stockholders’

 

 

Noncontrolling

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

 

Interest

 

 

Equity

 

Balances as of January 1, 2022

 

 

261,871,587

 

 

$

2,620

 

 

$

2,054,275

 

 

$

(6,353

)

 

$

(811,284

)

 

$

1,239,258

 

 

$

21,617

 

 

$

1,260,875

 

Exercise of common stock options

 

 

976,644

 

 

 

10

 

 

 

2,455

 

 

 

 

 

 

 

 

 

2,465

 

 

 

 

 

 

2,465

 

Vesting of restricted stock units

 

 

1,398,305

 

 

 

14

 

 

 

(14

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of stock under employee stock purchase plan

 

 

425,114

 

 

 

4

 

 

 

1,497

 

 

 

 

 

 

 

 

 

1,501

 

 

 

 

 

 

1,501

 

Issuance of common stock related to Conversa earn-out settlement

 

 

1,020,964